• LAST PRICE
    2.2400
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-1.3216%)
  • Bid / Lots
    2.2200/ 4
  • Ask / Lots
    2.2600/ 3
  • Open / Previous Close
    2.2100 / 2.2700
  • Day Range
    Low 2.2100
    High 2.3400
  • 52 Week Range
    Low 1.8500
    High 44.8000
  • Volume
    20,388
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 2.27
TimeVolumeBPTH
09:32 ET10242.3
09:34 ET3012.3
09:36 ET8002.33
09:38 ET2502.3072
09:39 ET2112.3
09:41 ET4002.3032
09:43 ET12002.34
09:45 ET5002.33
09:50 ET49862.27
09:52 ET26182.2501
09:54 ET8002.2817
09:56 ET4002.26
09:57 ET10512.265
09:59 ET30002.221
10:01 ET2002.24
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBPTH
Bio Path Holdings Inc
3.8M
-0.1x
---
United StatesREVB
Revelation Biosciences Inc
3.8M
-0.1x
---
United StatesNEXI
Neximmune Inc
3.8M
-0.1x
---
United StatesPKTX
ProtoKinetix Inc
3.7M
-8.8x
---
United StatesPHIO
Phio Pharmaceuticals Corp
3.9M
-0.2x
---
United StatesCPMV
Mosaic Immunoengineering Inc
4.0M
-4.4x
---
As of 2024-06-20

Company Information

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Contact Information

Headquarters
4710 BELLAIRE BOULEVARD, SUITE 210BELLAIRE, TX, United States 77401
Phone
832-742-1357
Fax
916-443-1908

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
Peter Nielsen
Director of Investor Relations, Secretary, Director
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Aline Sherwood

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.8M
Revenue (TTM)
$0.00
Shares Outstanding
1.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.31
EPS
$-27.39
Book Value
$0.71
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.